ABCELLERA BIOLOGICS INC., 10-Q filed on 5/11/2026
Quarterly Report
v3.26.1
Cover - shares
3 Months Ended
Mar. 31, 2026
May 07, 2026
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2026  
Document Transition Report false  
Entity File Number 001-39781  
Entity Registrant Name AbCellera Biologics Inc.  
Entity Incorporation, State or Country Code A1  
Entity Address, Address Line One 150 W 4th Avenue  
Entity Address, City or Town Vancouver  
Entity Address, State or Province BC  
Entity Address, Postal Zip Code V5Y 1G6  
City Area Code 604  
Local Phone Number 559-9005  
Title of 12(b) Security Common shares, no par value per share  
Trading Symbol ABCL  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   305,375,393
Entity Central Index Key 0001703057  
Current Fiscal Year End Date --12-31  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2026  
Amendment Flag false  
v3.26.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
Current assets:    
Cash and cash equivalents $ 77,063 $ 128,513
Marketable securities 427,669 405,313
Total cash, cash equivalents, and marketable securities 504,732 533,826
Accounts and accrued receivable 36,761 58,293
Restricted cash 25,000 25,000
Other current assets 98,103 111,113
Total current assets 664,596 728,232
Long-term assets:    
Property and equipment, net 422,806 428,003
Intangible assets, net 37,460 38,381
Goodwill 47,806 47,806
Investments in equity accounted investees 65,308 62,580
Other long-term assets 69,136 51,948
Total long-term assets 642,516 628,718
Total assets 1,307,112 1,356,950
Current liabilities:    
Accounts payable and other current liabilities 39,551 50,781
Deferred revenue 7,743 13,526
Total current liabilities 47,294 64,307
Long-term liabilities:    
Operating lease liability 134,309 137,403
Deferred government contributions 176,105 174,453
Other long-term liabilities 11,321 13,883
Total long-term liabilities 321,735 325,739
Total liabilities 369,029 390,046
Commitments and contingencies
Shareholders' equity:    
Common shares: no par value, unlimited authorized shares at December 31, 2025 and March 31, 2026: 300,600,710 and 303,945,581 shares issued and outstanding at December 31, 2025 and March 31, 2026, respectively 816,533 802,341
Additional paid-in capital 196,616 198,279
Accumulated other comprehensive loss (2,419) (4,234)
Accumulated deficit (72,647) (29,482)
Total shareholders' equity 938,083 966,904
Total liabilities and shareholders' equity $ 1,307,112 $ 1,356,950
v3.26.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
3 Months Ended 12 Months Ended
Mar. 31, 2026
Dec. 31, 2025
Statement of Financial Position [Abstract]    
Common stock, no par value (in dollars per share) $ 0 $ 0
Common Stock, Shares Authorized, Unlimited [Fixed List] Unlimited Unlimited
Common stock, shares issued (in shares) 303,945,581 300,600,710
Common stock, shares outstanding (in shares) 303,945,581 300,600,710
v3.26.1
Condensed Consolidated Statements of Loss and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenue:    
Total revenue $ 8,315 $ 4,235
Operating expenses:    
Research and development [1] 46,662 42,496
Sales, general, and administrative [1] 12,334 19,068
Depreciation and amortization 6,838 5,331
Total operating expenses 65,834 66,895
Loss from operations (57,519) (62,660)
Other income:    
Interest and other (3,643) (5,523)
Grants and incentives (4,339) (4,153)
Total other income (7,982) (9,676)
Loss before income tax (49,537) (52,984)
Income tax recovery (6,372) (7,363)
Net loss (43,165) (45,621)
Foreign currency translation adjustment 1,815 (2,620)
Comprehensive loss $ (41,350) $ (48,241)
Net loss per share    
Basic (in dollars per share) $ (0.14) $ (0.15)
Diluted (in dollars per share) $ (0.14) $ (0.15)
Weighted-average common shares outstanding    
Basic (in shares) 303,074,605 297,692,663
Diluted (in shares) 303,074,605 297,692,663
Research fees    
Revenue:    
Total revenue $ 8,124 $ 4,068
Licensing and royalty revenue    
Revenue:    
Total revenue $ 191 $ 167
[1] Exclusive of depreciation and amortization
v3.26.1
Condensed Consolidated Statements of Stockholders’ Equity - USD ($)
$ in Thousands
Total
Common Shares
Additional Paid-in Capital
Accumulated Earnings (Deficit)
Accumulated Other Comprehensive Loss
Beginning balances (in shares) at Dec. 31, 2024   295,757,002      
Beginning balances at Dec. 31, 2024 $ 1,056,084 $ 777,171 $ 166,361 $ 116,930 $ (4,378)
Number of Shares          
Shares issued and restricted stock units ("RSUs") vested under stock option plan (in shares)   2,598,750      
Shares issued and restricted stock units (“RSUs”) vested under stock option plan 151 $ 12,897 (12,746)    
Stock-based compensation 14,988   14,988    
Foreign currency translation adjustment (2,620)       (2,620)
Net loss (45,621)     (45,621)  
Ending balances (in shares) at Mar. 31, 2025   298,355,752      
Ending balances at Mar. 31, 2025 1,022,982 $ 790,068 168,603 71,309 (6,998)
Beginning balances (in shares) at Dec. 31, 2025   300,600,710      
Beginning balances at Dec. 31, 2025 966,904 $ 802,341 198,279 (29,482) (4,234)
Number of Shares          
Shares issued and restricted stock units ("RSUs") vested under stock option plan (in shares)   3,344,871      
Shares issued and restricted stock units (“RSUs”) vested under stock option plan 516 $ 14,192 (13,676)    
Stock-based compensation 12,013   12,013    
Foreign currency translation adjustment 1,815       1,815
Net loss (43,165)     (43,165)  
Ending balances (in shares) at Mar. 31, 2026   303,945,581      
Ending balances at Mar. 31, 2026 $ 938,083 $ 816,533 $ 196,616 $ (72,647) $ (2,419)
v3.26.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Cash flows from operating activities:    
Net loss $ (43,165) $ (45,621)
Cash flows from operating activities:    
Depreciation of property and equipment 5,918 4,409
Amortization of intangible assets 920 922
Amortization of operating lease right-of-use assets 1,817 1,274
Stock-based compensation 12,013 14,786
Other 2,377 2,213
Changes in operating assets and liabilities:    
Research fees and grants receivable 13,103 (1,133)
Income taxes payable (4,970) (4,408)
Accounts payable and accrued liabilities (9,406) (3,409)
Deferred revenue (8,033) 13,313
Deferred grant income (2,356) (1,220)
Other assets (1,741) 7,320
Net cash used in operating activities (33,523) (11,554)
Cash flows from investing activities:    
Purchases of property and equipment (3,831) (10,636)
Purchase of marketable securities (166,308) (164,990)
Proceeds from marketable securities 143,802 190,027
Receipt of grant funding 1,361 1,018
Long-term investments and other assets (105) (7,484)
Net cash provided by (used in) investing activities (25,081) 7,935
Cash flows from financing activities:    
Proceeds from long-term liabilities and other 7,192 5,970
Net cash provided by financing activities 7,192 5,970
Effect of exchange rate changes on cash and cash equivalents (38) 590
Increase (decrease) in cash and cash equivalents (51,450) 2,941
Cash and cash equivalents and restricted cash, beginning of period 155,249 183,615
Cash and cash equivalents and restricted cash, end of period 103,799 186,556
Restricted cash included in other assets 1,736 2,290
Total cash, cash equivalents, and restricted cash shown on the balance sheet 102,063 184,266
Supplemental disclosure of non-cash investing and financing activities    
Property and equipment in accounts payable 706 10,960
Right-of-use assets obtained in exchange for operating lease obligation $ 0 $ 3,361
v3.26.1
Nature of operations
3 Months Ended
Mar. 31, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of operations Nature of operations
AbCellera Biologics Inc.’s (the “Company”) is a clinical-stage biotechnology company focused on discovering and developing antibody medicines for indications with high unmet medical need. The Company aims to bring antibody drug candidates from target to clinic by combining expertise, technologies, and infrastructure for antibody drug discovery and development. The Company uses its capabilities to develop its own pipeline of future antibody drugs and has a diversified portfolio of royalty (and equivalent) stakes in future antibody drugs with partners.
v3.26.1
Basis of presentation
3 Months Ended
Mar. 31, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of presentation Basis of presentation
The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. Accordingly, the year-end condensed consolidated financial statement data was derived from audited financial statements and these financial statements do not include all the information and footnotes required for complete financial statements. These statements should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended December 31, 2025.
These unaudited interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three months ended March 31, 2025 and 2026 are not necessarily indicative of results that can be expected for a full year. These unaudited interim condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2025.
All amounts expressed in these condensed consolidated financial statements of the Company and the accompanying notes thereto are expressed in thousands of U.S. dollars, except for share data and where otherwise indicated. References to “$” are to U.S. dollars and references to “C$” and “CAD” are to Canadian dollars.
v3.26.1
Significant accounting policies
3 Months Ended
Mar. 31, 2026
Accounting Policies [Abstract]  
Significant accounting policies Significant accounting policies
Use of estimates
The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including estimated timing of completion of performance obligations and determining whether an option for additional goods or services represents a material right, the impairment assessment of intangible assets and goodwill, and the estimates associated with stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates.
Recent accounting pronouncements
The Company has reviewed recent accounting pronouncements in the three months ended March 31, 2026 and concluded that they are either not applicable to the Company or no material impact is expected in the condensed consolidated financial statements as a result of future adoption.
v3.26.1
Net loss per share
3 Months Ended
Mar. 31, 2026
Earnings Per Share [Abstract]  
Net loss per share Net loss per share
Basic and diluted net loss per share was calculated as follows:
Three months ended March 31,
Basic and diluted loss per share20252026
Net loss$(45,621)$(43,165)
Weighted-average common shares outstanding297,692,663303,074,605
Net loss per share - basic and diluted$(0.15)$(0.14)
The Company’s potentially dilutive securities, which include stock options and restricted share units (“RSUs”), have been excluded from the computation of diluted net loss per share for the three months ended March 31, 2025 and March 31, 2026 as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding for the three months ended March 31, 2025 and March 31, 2026 used to calculate both basic and diluted net loss per share is the same.
The Company excluded 71,947,646 and 79,140,601 potential common shares for the three months ended March 31, 2025 and 2026, respectively, from the computation of diluted net loss per share because including them would have had an anti-dilutive effect.
v3.26.1
Property and equipment, net
3 Months Ended
Mar. 31, 2026
Property, Plant and Equipment [Abstract]  
Property and equipment, net Property and equipment, net
Property and equipment, net consisted of the following:
December 31, 2025March 31, 2026
Land$53,405 $53,405 
Building and building improvements193,160 194,834 
Equipment102,935 103,801 
Operating lease right-of-use assets136,117 134,300 
Property and equipment485,617 486,340 
Less: accumulated depreciation(57,614)(63,534)
Property and equipment, net$428,003 $422,806 
Depreciation expense on property and equipment for the three months ended March 31, 2025 and 2026 was $4.4 million and $5.9 million, respectively.
v3.26.1
Intangible assets
3 Months Ended
Mar. 31, 2026
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible assets Intangible assets
Intangible assets consisted of the following:
December 31, 2025March 31, 2026
Gross
carrying
amount
Accumulated
amortization
Net book
value
Gross
carrying
amount
Accumulated
amortization
Net book
value
License$16,620 $8,968 $7,652 $16,620 $9,370 $7,250 
Technology52,700 21,971 30,729 52,700 22,490 30,210 
Total$69,320 $30,939 $38,381 $69,320 $31,860 $37,460 
Amortization expense on intangible assets subject to amortization is estimated to be as follows for each of the next five years ended March 31:
Amortization
Expense
2027$3,732 
20283,732 
20293,732 
20303,686 
20312,326 
$17,208 
v3.26.1
Investments in equity accounted investees, and other assets
3 Months Ended
Mar. 31, 2026
Equity Method Investments and Joint Ventures [Abstract]  
Investments in equity accounted investees, and other assets Investments in equity accounted investees and other assets
The Company has entered into two separate 50% joint ventures, Dayhu JV and Beedie JV, as part of the construction of new office and laboratory headquarters. The Company recorded immaterial amounts of proportionate income or loss with respect to either venture in the three months ended March 31, 2025 and 2026.
Dayhu JV
As of December 31, 2025 and March 31, 2026, the equity investment balance was $10.8 million and $11.5 million, respectively, of which substantially all the assets in the Dayhu JV are comprised of property and equipment. As of December 31, 2025 and March 31, 2026, the Company recorded a right-of-use asset of $45.9 million and $45.2 million, respectively, and an operating lease liability of $46.7 million and $45.6 million, respectively, associated with an office lease with the Dayhu JV. In the three months ended March 31, 2025 and 2026, the Company incurred lease expense of $1.2 million and $1.3 million, respectively, to the Dayhu JV included within operating expenses.
As of December 31, 2025 and March 31, 2026, the Dayhu JV’s fixed-rate mortgage had a balance of $61.2 million and $60.2 million, respectively. The Company provides a limited guarantee of the JV's loan obligations, capped at CAD $42.0 million ($30.6 million), which matches a corresponding guarantee provided by the Dayhu JV partner.
Beedie JV
As of December 31, 2025 and March 31, 2026, the equity investment balance was $51.8 million and $53.8 million, respectively, of which substantially all the assets in the Beedie JV are comprised of property and equipment. As of December 31, 2025 and March 31, 2026, the Company recorded a right-of-use asset of $71.5 million and $71.0 million, respectively, and an operating lease liability of $75.7 million and $74.4 million, respectively, associated with an office lease with the Beedie JV. In the three months ended March 31, 2025 and 2026, the Company incurred lease expense of nil and $1.8 million, respectively, to the Beedie JV included within operating expenses.
The Company had a loan receivable balance of $39.4 million and $39.2 million at December 31, 2025 and March 31, 2026, respectively, included within other current assets. The loan receivable is directly with our JV partner, Beedie, which relates to the land and construction loan that matures in February 2027.
v3.26.1
Other current assets and liabilities
3 Months Ended
Mar. 31, 2026
Payables and Accruals [Abstract]  
Other current assets and liabilities Other current assets and liabilities
Other current assets
December 31, 2025March 31, 2026
Taxes receivable$55,695 $39,800 
Prepaid expenses and other9,670 11,279 
Materials and supplies6,336 7,860 
Loans receivable from JV partners39,412 39,164 
Total other current assets$111,113 $98,103 
Current accounts payable and other current liabilities
December 31, 2025March 31, 2026
Accounts payable and accrued liabilities$25,228 $20,808 
Current portion of operating lease liability5,815 5,869 
Payroll liabilities10,755 3,926 
Current portion of deferred government contribution8,983 8,948 
Total accounts payable and other current liabilities$50,781 $39,551 
v3.26.1
Shareholders’ equity
3 Months Ended
Mar. 31, 2026
Share-Based Payment Arrangement [Abstract]  
Shareholders' equity Shareholders’ equity
The following table summarizes the Company’s stock option activity under the Pre-IPO Plan since December 31, 2025:
Number of
Shares
Weighted-
Average Exercise
Price 
Outstanding as of December 31, 202524,089,219$1.07 
Granted– 
Exercised(825,281)0.22 
Forfeited– 
Outstanding as of March 31, 202623,263,938$1.10 
Options exercisable as of March 31, 202623,263,938$1.10 
The following table summarizes the Company’s stock option activity under the 2020 Plan since December 31, 2025:
Number of
Shares
Weighted-
Average Exercise
Price
Outstanding as of December 31, 202536,376,041$7.38 
Granted10,103,5583.43 
Exercised(103,287)2.99 
Forfeited(640,277)5.73 
Outstanding as of March 31, 202645,736,035$6.54 
Options exercisable as of March 31, 202620,191,253$9.82 
The following table summarizes the Company’s RSU activity under the 2020 Plan since December 31, 2025:
Number of
Shares
Weighted-
Average Grant
Date Fair Value
Outstanding as of December 31, 20258,837,384$4.75 
Granted4,055,2813.43 
Vested and settled(2,416,303)5.51 
Forfeited(335,734)4.72 
Outstanding as of March 31, 202610,140,628$4.04 
As of March 31, 2026, the number of shares available for issuance under the 2020 Plan was 33,758,986, which includes awards granted and outstanding under the Pre-IPO Plan that are forfeited after December 10, 2020.
Stock-based compensation:
Stock-based compensation was classified in the condensed consolidated statements of loss and comprehensive loss as follows:
Three months ended March 31,
20252026
Research and development expenses$8,136 $7,039 
Sales, general, and administrative expenses6,650 4,974 
 $14,786 $12,013 
v3.26.1
Revenue
3 Months Ended
Mar. 31, 2026
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
The disaggregated revenue categories are presented on the face of the condensed consolidated statements of loss and comprehensive loss. Deferred revenue outstanding in each respective period is as follows:
December 31, 2024March 31, 2025December 31, 2025March 31, 2026
Deferred revenue$19,221 $32,535 $17,026 $8,993 
During the three months ended March 31, 2025 and 2026, the Company recognized $2.6 million, and $7.9 million, respectively, that was included in deferred revenue at the end of the preceding periods. Additionally, during the three months ended March 31, 2026, the Company collected $18.0 million of the $36.0 million litigation settlement receivable outstanding as of December 31, 2025.
v3.26.1
Financial instruments
3 Months Ended
Mar. 31, 2026
Investments, All Other Investments [Abstract]  
Financial instruments Financial instruments
Fair Value Measurements
The Company categorizes its financial assets and liabilities measured at fair value into a three-level hierarchy established by U.S. GAAP that prioritizes those inputs to valuation techniques used to measure fair value based on the degree to which they are observable. The three levels of the fair value hierarchy are as follows: Level 1 inputs are quoted prices in active markets for identical assets and liabilities; Level 2 inputs, other than quoted prices included within Level 1, are observable for the asset or liability either directly or indirectly; and Level 3 inputs are not observable in the market.
The Company’s financial instruments consist of cash and cash equivalents, restricted cash, marketable securities, accounts receivable, loans receivable, and accounts payable and other liabilities. The carrying values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and other liabilities, and loans receivable, approximate their fair values, and are primarily classified as Level 2.
At March 31, 2026, the Company also held non-marketable securities included in other long-term assets of $32.5 million (December 31, 2025 - $32.5 million). These non-marketable securities are measured at cost less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.
Marketable Securities
As part of the Company’s cash management strategy, the Company holds high credit quality marketable securities that are available to support the Company’s current operations. As of March 31, 2026, our marketable securities were rated A- or higher (or its equivalent) by at least two of the major rating agencies with a weighted average life of approximately 0.6 years.
Level 2 marketable securities in the fair value hierarchy were based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs to determine fair value. There were no transfers between Level 1, Level 2 and Level 3 during the period.
The following table presents information about the Company’s marketable securities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such fair values:
Fair Value Measurements at March 31, 2026:
Level 1Level 2Level 3Total
Marketable securities
U.S. government agencies$63,482 $– $– $63,482 
Certificate of deposit– 105,629 – 105,629 
Commercial paper– 41,313 – 41,313 
Corporate bonds– 144,774 – 144,774 
Asset backed securities– 72,471 – 72,471 
$63,482 $364,187 $– $427,669 
v3.26.1
Commitments and contingencies
3 Months Ended
Mar. 31, 2026
Commitments and Contingencies Disclosure [Abstract]  
Commitments and contingencies Commitments and contingencies
From time to time, the Company may become involved in routine litigation arising in the ordinary course of business. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company does not have contingency reserves established for any litigation liabilities and any of the costs related to such legal proceedings are expensed as incurred.
The Company may enter into certain agreements with strategic partners in the ordinary course of operations that may include investments in collaborative arrangements, contractual milestone payments related to the achievement of pre-specified research, development, regulatory and commercialization events and indemnification provisions, which are common in such agreements.
Pursuant to the agreements, the Company may be obligated to make research and development and regulatory milestone payments upon the occurrence of certain events and upon receipt of royalty payments in the low single-digits to mid-twenties based on certain net sales targets. Immaterial amounts were expensed during the three months ended March 31, 2025 or March 31, 2026.
v3.26.1
Government Contributions
3 Months Ended
Mar. 31, 2026
Government Assistance [Abstract]  
Government contributions Government contributions
The Company recognized the following on the consolidated balance sheets:
March 31, 2026
Deferred Government Contribution
Accounts Receivable5
Government Grant1
Total
Non-repayableConditionally RepayableRepayable
Government Contribution 1 (Canada)2
$– $1,367 $76,772 $– $78,139 
Government Contribution 2 (Canada)3
12,486 10,678 – 70,473 81,151 
Government Contribution 2 (British Columbia)4
17,716 – 24,789 – 24,789 
Other Government Grants– 974 – – 974 
March 31, 2026$30,202 $13,019 $101,561 $70,473 $185,053 
December 31, 2025$33,592 $13,690 $103,247 $66,499 $183,436 
March 31, 2026
Current$17,661 $2,299 $6,649 $– $8,948 
Long-term$12,541 $10,720 $94,912 $70,473 $176,105 
1No amounts have been accrued related to the repayment terms as the conditions are estimated to be non-probable.
2As of December 31, 2024, the Company had incurred the maximum expenditures under the agreement. Repayment of CAD $116.9 million ($88.5 million) of the funded amount is conditional on achieving certain revenue thresholds over a specified period of time.
3The funding includes repayable and conditionally repayable amounts starting in 2033 over 15 years, where the conditional portion is based on certain revenue thresholds, at a factor of up to 1.4 times the original grant. As of March 31, 2026, total available undrawn grant funding was approximately CAD $111.8 million ($80.2 million), consisting of CAD $94.4 million ($67.8 million) for future qualifying expenditures and $12.5 million in accrued grants receivable for which claims will be filed subsequently.
4Conditionally repayable amounts starting in 2032 over up to fifteen years, based on certain revenue thresholds. As of March 31, 2026, total available undrawn grant funding was approximately CAD $60.2 million ($43.2 million), consisting of CAD $35.5 million ($25.5 million) for future qualifying expenditures and $17.7 million in accrued grants receivable for which claims will be filed subsequently.
5During the three months ended March 31, 2026, the Company recognized non-cash investing and financing activities for uncollected government grants of $0.2 million and $4.9 million, respectively (2025: $0.8 million and $8.3 million).
v3.26.1
Insider Trading Arrangements
3 Months Ended
Mar. 31, 2026
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.26.1
Significant accounting policies (Policies)
3 Months Ended
Mar. 31, 2026
Accounting Policies [Abstract]  
Basis of presentation
The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. Accordingly, the year-end condensed consolidated financial statement data was derived from audited financial statements and these financial statements do not include all the information and footnotes required for complete financial statements. These statements should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended December 31, 2025.
Consolidation
The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. Accordingly, the year-end condensed consolidated financial statement data was derived from audited financial statements and these financial statements do not include all the information and footnotes required for complete financial statements. These statements should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended December 31, 2025.
Use of estimates
Use of estimates
The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including estimated timing of completion of performance obligations and determining whether an option for additional goods or services represents a material right, the impairment assessment of intangible assets and goodwill, and the estimates associated with stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates.
Recent accounting pronouncements
Recent accounting pronouncements
The Company has reviewed recent accounting pronouncements in the three months ended March 31, 2026 and concluded that they are either not applicable to the Company or no material impact is expected in the condensed consolidated financial statements as a result of future adoption.
v3.26.1
Net loss per share (Tables)
3 Months Ended
Mar. 31, 2026
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Net Loss Per Share
Basic and diluted net loss per share was calculated as follows:
Three months ended March 31,
Basic and diluted loss per share20252026
Net loss$(45,621)$(43,165)
Weighted-average common shares outstanding297,692,663303,074,605
Net loss per share - basic and diluted$(0.15)$(0.14)
v3.26.1
Property and equipment, net (Tables)
3 Months Ended
Mar. 31, 2026
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment, Net
Property and equipment, net consisted of the following:
December 31, 2025March 31, 2026
Land$53,405 $53,405 
Building and building improvements193,160 194,834 
Equipment102,935 103,801 
Operating lease right-of-use assets136,117 134,300 
Property and equipment485,617 486,340 
Less: accumulated depreciation(57,614)(63,534)
Property and equipment, net$428,003 $422,806 
v3.26.1
Intangible assets (Tables)
3 Months Ended
Mar. 31, 2026
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets
Intangible assets consisted of the following:
December 31, 2025March 31, 2026
Gross
carrying
amount
Accumulated
amortization
Net book
value
Gross
carrying
amount
Accumulated
amortization
Net book
value
License$16,620 $8,968 $7,652 $16,620 $9,370 $7,250 
Technology52,700 21,971 30,729 52,700 22,490 30,210 
Total$69,320 $30,939 $38,381 $69,320 $31,860 $37,460 
Schedule of Estimated Amortization Expense on Intangible Assets
Amortization expense on intangible assets subject to amortization is estimated to be as follows for each of the next five years ended March 31:
Amortization
Expense
2027$3,732 
20283,732 
20293,732 
20303,686 
20312,326 
$17,208 
v3.26.1
Other current assets and liabilities (Tables)
3 Months Ended
Mar. 31, 2026
Payables and Accruals [Abstract]  
Schedule of Other Current Assets
Other current assets
December 31, 2025March 31, 2026
Taxes receivable$55,695 $39,800 
Prepaid expenses and other9,670 11,279 
Materials and supplies6,336 7,860 
Loans receivable from JV partners39,412 39,164 
Total other current assets$111,113 $98,103 
Schedule of Current Accounts Payable and Other Current Liabilities
Current accounts payable and other current liabilities
December 31, 2025March 31, 2026
Accounts payable and accrued liabilities$25,228 $20,808 
Current portion of operating lease liability5,815 5,869 
Payroll liabilities10,755 3,926 
Current portion of deferred government contribution8,983 8,948 
Total accounts payable and other current liabilities$50,781 $39,551 
v3.26.1
Shareholders’ equity (Tables)
3 Months Ended
Mar. 31, 2026
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock Option Activity
The following table summarizes the Company’s stock option activity under the Pre-IPO Plan since December 31, 2025:
Number of
Shares
Weighted-
Average Exercise
Price 
Outstanding as of December 31, 202524,089,219$1.07 
Granted– 
Exercised(825,281)0.22 
Forfeited– 
Outstanding as of March 31, 202623,263,938$1.10 
Options exercisable as of March 31, 202623,263,938$1.10 
The following table summarizes the Company’s stock option activity under the 2020 Plan since December 31, 2025:
Number of
Shares
Weighted-
Average Exercise
Price
Outstanding as of December 31, 202536,376,041$7.38 
Granted10,103,5583.43 
Exercised(103,287)2.99 
Forfeited(640,277)5.73 
Outstanding as of March 31, 202645,736,035$6.54 
Options exercisable as of March 31, 202620,191,253$9.82 
Schedule of Restricted Share Units Activity
The following table summarizes the Company’s RSU activity under the 2020 Plan since December 31, 2025:
Number of
Shares
Weighted-
Average Grant
Date Fair Value
Outstanding as of December 31, 20258,837,384$4.75 
Granted4,055,2813.43 
Vested and settled(2,416,303)5.51 
Forfeited(335,734)4.72 
Outstanding as of March 31, 202610,140,628$4.04 
Schedule of Stock-Based Compensation Expense
Stock-based compensation was classified in the condensed consolidated statements of loss and comprehensive loss as follows:
Three months ended March 31,
20252026
Research and development expenses$8,136 $7,039 
Sales, general, and administrative expenses6,650 4,974 
 $14,786 $12,013 
v3.26.1
Revenue (Tables)
3 Months Ended
Mar. 31, 2026
Revenue from Contract with Customer [Abstract]  
Schedule of Deferred Revenue Outstanding Deferred revenue outstanding in each respective period is as follows:
December 31, 2024March 31, 2025December 31, 2025March 31, 2026
Deferred revenue$19,221 $32,535 $17,026 $8,993 
v3.26.1
Financial instruments (Tables)
3 Months Ended
Mar. 31, 2026
Investments, All Other Investments [Abstract]  
Schedule of Financial Assets Measured at Fair Value on Recurring Basis
The following table presents information about the Company’s marketable securities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such fair values:
Fair Value Measurements at March 31, 2026:
Level 1Level 2Level 3Total
Marketable securities
U.S. government agencies$63,482 $– $– $63,482 
Certificate of deposit– 105,629 – 105,629 
Commercial paper– 41,313 – 41,313 
Corporate bonds– 144,774 – 144,774 
Asset backed securities– 72,471 – 72,471 
$63,482 $364,187 $– $427,669 
v3.26.1
Government contributions (Tables)
3 Months Ended
Mar. 31, 2026
Government Assistance [Abstract]  
Schedule of Government Assistance
The Company recognized the following on the consolidated balance sheets:
March 31, 2026
Deferred Government Contribution
Accounts Receivable5
Government Grant1
Total
Non-repayableConditionally RepayableRepayable
Government Contribution 1 (Canada)2
$– $1,367 $76,772 $– $78,139 
Government Contribution 2 (Canada)3
12,486 10,678 – 70,473 81,151 
Government Contribution 2 (British Columbia)4
17,716 – 24,789 – 24,789 
Other Government Grants– 974 – – 974 
March 31, 2026$30,202 $13,019 $101,561 $70,473 $185,053 
December 31, 2025$33,592 $13,690 $103,247 $66,499 $183,436 
March 31, 2026
Current$17,661 $2,299 $6,649 $– $8,948 
Long-term$12,541 $10,720 $94,912 $70,473 $176,105 
1No amounts have been accrued related to the repayment terms as the conditions are estimated to be non-probable.
2As of December 31, 2024, the Company had incurred the maximum expenditures under the agreement. Repayment of CAD $116.9 million ($88.5 million) of the funded amount is conditional on achieving certain revenue thresholds over a specified period of time.
3The funding includes repayable and conditionally repayable amounts starting in 2033 over 15 years, where the conditional portion is based on certain revenue thresholds, at a factor of up to 1.4 times the original grant. As of March 31, 2026, total available undrawn grant funding was approximately CAD $111.8 million ($80.2 million), consisting of CAD $94.4 million ($67.8 million) for future qualifying expenditures and $12.5 million in accrued grants receivable for which claims will be filed subsequently.
4Conditionally repayable amounts starting in 2032 over up to fifteen years, based on certain revenue thresholds. As of March 31, 2026, total available undrawn grant funding was approximately CAD $60.2 million ($43.2 million), consisting of CAD $35.5 million ($25.5 million) for future qualifying expenditures and $17.7 million in accrued grants receivable for which claims will be filed subsequently.
5During the three months ended March 31, 2026, the Company recognized non-cash investing and financing activities for uncollected government grants of $0.2 million and $4.9 million, respectively (2025: $0.8 million and $8.3 million).
v3.26.1
Net loss per share - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Basic loss per share    
Net loss $ (43,165) $ (45,621)
Weighted-average common shares outstanding - basic (in shares) 303,074,605 297,692,663
Net loss per share - basic (in dollars per share) $ (0.14) $ (0.15)
Diluted loss per share    
Net loss $ (43,165) $ (45,621)
Weighted-average common shares outstanding - diluted (in shares) 303,074,605 297,692,663
Net loss per share - diluted (in dollars per share) $ (0.14) $ (0.15)
v3.26.1
Net loss per share - Additional Information (Details) - shares
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Earnings Per Share [Abstract]    
Total potential common shares excluded (in shares) 79,140,601 71,947,646
v3.26.1
Property and equipment, net - Schedule of Property and Equipment, Net (Details) - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
Property Plant And Equipment [Line Items]    
Operating lease right-of-use assets $ 134,300 $ 136,117
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Property and equipment, net Property and equipment, net
Property and equipment $ 486,340 $ 485,617
Less: accumulated depreciation (63,534) (57,614)
Property and equipment, net 422,806 428,003
Land    
Property Plant And Equipment [Line Items]    
Property and equipment, gross 53,405 53,405
Building and building improvements    
Property Plant And Equipment [Line Items]    
Property and equipment, gross 194,834 193,160
Equipment    
Property Plant And Equipment [Line Items]    
Property and equipment, gross $ 103,801 $ 102,935
v3.26.1
Property and equipment, net - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Property, Plant and Equipment [Abstract]    
Depreciation expense on property and equipment $ 5,918 $ 4,409
v3.26.1
Intangible assets - Schedule of Intangible Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
Finite Lived Intangible Assets [Line Items]    
Gross carrying amount $ 69,320 $ 69,320
Accumulated amortization 31,860 30,939
Net book value 37,460 38,381
License    
Finite Lived Intangible Assets [Line Items]    
Gross carrying amount 16,620 16,620
Accumulated amortization 9,370 8,968
Net book value 7,250 7,652
Technology    
Finite Lived Intangible Assets [Line Items]    
Gross carrying amount 52,700 52,700
Accumulated amortization 22,490 21,971
Net book value $ 30,210 $ 30,729
v3.26.1
Intangible assets - Schedule of Estimated Amortization Expense on Intangible Assets (Details)
$ in Thousands
Mar. 31, 2026
USD ($)
Amortization Expense  
2027 $ 3,732
2028 3,732
2029 3,732
2030 3,686
2031 2,326
Finite lived intangible assets amortization expense $ 17,208
v3.26.1
Investments in equity accounted investees, and other assets (Details)
$ in Thousands, $ in Millions
3 Months Ended 12 Months Ended
Mar. 31, 2026
USD ($)
jointVenture
Mar. 31, 2026
CAD ($)
jointVenture
Mar. 31, 2025
USD ($)
Dec. 31, 2025
CAD ($)
Dec. 31, 2025
USD ($)
Schedule Of Equity Method Investments [Line Items]          
Number of joint ventures | jointVenture 2 2      
Operating lease right-of-use assets $ 134,300       $ 136,117
Dayhu JV          
Schedule Of Equity Method Investments [Line Items]          
Equity method investments, ownership percent 50.00%        
Equity investment balance, contributions made in joint venture $ 11,500       10,800
Operating lease right-of-use assets 45,200       45,900
Lease liability 45,600       46,700
Lease expense 1,300   $ 1,200    
Fixed rate mortgage $ 60,200       61,200
Dayhu JV | Daylu JV Loan          
Schedule Of Equity Method Investments [Line Items]          
Equity method investment commitment amount   $ 30.6   $ 42.0  
Beedie JV          
Schedule Of Equity Method Investments [Line Items]          
Equity method investments, ownership percent 50.00%        
Equity investment balance, contributions made in joint venture $ 53,800       51,800
Operating lease right-of-use assets 71,000       71,500
Lease liability 74,400       75,700
Lease expense 1,800   $ 0    
Loan receivable $ 39,200       $ 39,400
v3.26.1
Other current assets and liabilities - Other Current Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
Payables and Accruals [Abstract]    
Taxes receivable $ 39,800 $ 55,695
Prepaid expenses and other 11,279 9,670
Materials and supplies 7,860 6,336
Loans receivable from JV partners 39,164 39,412
Total other current assets $ 98,103 $ 111,113
v3.26.1
Other current assets and liabilities - Schedule of Accounts Payable and Other Current Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
Payables and Accruals [Abstract]    
Accounts payable and accrued liabilities $ 20,808 $ 25,228
Current portion of operating lease liability $ 5,869 $ 5,815
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Total accounts payable and other current liabilities Total accounts payable and other current liabilities
Payroll liabilities $ 3,926 $ 10,755
Current portion of deferred government contribution 8,948 8,983
Total accounts payable and other current liabilities $ 39,551 $ 50,781
v3.26.1
Shareholders’ equity - Schedule of Stock Option Activity (Details)
3 Months Ended
Mar. 31, 2026
$ / shares
shares
Pre-IPO Plan  
Number of Shares  
Outstanding, beginning balance (in shares) | shares 24,089,219
Granted (in shares) | shares 0
Exercised (in shares) | shares (825,281)
Forfeited (in shares) | shares 0
Outstanding, ending balance (in shares) | shares 23,263,938
Options exercisable (in shares) | shares 23,263,938
Weighted- Average Exercise Price   
Outstanding, beginning balance (in dollars per share) | $ / shares $ 1.07
Granted (in dollars per share) | $ / shares 0
Exercised (in dollars per share) | $ / shares 0.22
Forfeited (in dollars per share) | $ / shares 0
Outstanding, ending balance (in dollars per share) | $ / shares 1.10
Weighted- Average Exercise Price, Options exercisable (in dollars per share) | $ / shares $ 1.10
2020 Share Option and Incentive Plan  
Number of Shares  
Outstanding, beginning balance (in shares) | shares 36,376,041
Granted (in shares) | shares 10,103,558
Exercised (in shares) | shares (103,287)
Forfeited (in shares) | shares (640,277)
Outstanding, ending balance (in shares) | shares 45,736,035
Options exercisable (in shares) | shares 20,191,253
Weighted- Average Exercise Price   
Outstanding, beginning balance (in dollars per share) | $ / shares $ 7.38
Granted (in dollars per share) | $ / shares 3.43
Exercised (in dollars per share) | $ / shares 2.99
Forfeited (in dollars per share) | $ / shares 5.73
Outstanding, ending balance (in dollars per share) | $ / shares 6.54
Weighted- Average Exercise Price, Options exercisable (in dollars per share) | $ / shares $ 9.82
v3.26.1
Shareholders’ equity - Schedule of Restricted Share Units Activity (Details) - 2020 Share Option and Incentive Plan - Restricted Share Units (RSUs)
3 Months Ended
Mar. 31, 2026
$ / shares
shares
Number of Shares  
Outstanding, beginning balance (in shares) | shares 8,837,384
Granted (in shares) | shares 4,055,281
Vested and settled (in shares) | shares (2,416,303)
Forfeited (in shares) | shares (335,734)
Outstanding, ending balance (in shares) | shares 10,140,628
Weighted- Average Grant Date Fair Value  
Outstanding, beginning balance (in dollars per share) | $ / shares $ 4.75
Granted (in dollars per share) | $ / shares 3.43
Vested and settled (in dollars per share) | $ / shares 5.51
Forfeited (in dollars per share) | $ / shares 4.72
Outstanding, ending balance (in dollars per share) | $ / shares $ 4.04
v3.26.1
Shareholders’ equity - Additional Information (Details)
Mar. 31, 2026
shares
2020 Share Option and Incentive Plan  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Number of shares available for issuance (in shares) 33,758,986
v3.26.1
Shareholders' equity - Schedule of Stock-Based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Stock-based compensation expense $ 12,013 $ 14,786
Research and development expenses    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Stock-based compensation expense 7,039 8,136
Sales, general, and administrative expenses    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Stock-based compensation expense $ 4,974 $ 6,650
v3.26.1
Revenue - Schedule of Deferred Revenue Outstanding (Details) - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
Mar. 31, 2025
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]        
Deferred revenue $ 8,993 $ 17,026 $ 32,535 $ 19,221
v3.26.1
Revenue - Additional Information (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Revenue from Contract with Customer [Abstract]      
Contract with customer liability, revenue recognized $ 7.9 $ 2.6  
Proceeds from legal settlements $ 18.0    
Litigation settlement receivable     $ 36.0
v3.26.1
Financial instruments - Additional Information (Details) - USD ($)
$ in Millions
Mar. 31, 2026
Dec. 31, 2025
Investments, All Other Investments [Abstract]    
Long term assets $ 32.5 $ 32.5
Term of securities (in years) 7 months 6 days  
v3.26.1
Financial Instruments - Schedule of Financial Assets Measured at Fair Value on Recurring Basis (Details) - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Marketable securities $ 427,669 $ 405,313
U.S. government agencies    
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Marketable securities 63,482  
Certificate of deposit    
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Marketable securities 105,629  
Commercial paper    
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Marketable securities 41,313  
Corporate bonds    
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Marketable securities 144,774  
Asset backed securities    
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Marketable securities 72,471  
Level 1    
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Marketable securities 63,482  
Level 1 | U.S. government agencies    
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Marketable securities 63,482  
Level 2    
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Marketable securities 364,187  
Level 2 | Certificate of deposit    
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Marketable securities 105,629  
Level 2 | Commercial paper    
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Marketable securities 41,313  
Level 2 | Corporate bonds    
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Marketable securities 144,774  
Level 2 | Asset backed securities    
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Marketable securities $ 72,471  
v3.26.1
Government contributions (Details)
$ in Thousands, $ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
May 31, 2023
Mar. 31, 2026
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2024
CAD ($)
Mar. 31, 2026
CAD ($)
Government Assistance [Line Items]            
Government Assistance Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag   Government Contribution 1 (Canada)2        
Accounts Receivable   $ 30,202 $ 33,592      
Deferred Government Contribution   185,053 183,436      
Accounts Receivable, Current   17,661        
Deferred Government Contribution, Current   8,948        
Accounts Receivable, Long-Term   12,541        
Deferred Government Contributions, Long-Term   176,105 174,453      
Non-cash investing activities   200 800      
Non-cash financing activities   4,900 8,300      
Other Government Grants            
Government Assistance [Line Items]            
Accounts Receivable   0        
Deferred Government Contribution   974        
Canada | Government Contribution 1            
Government Assistance [Line Items]            
Accounts Receivable   0        
Deferred Government Contribution   78,139        
Canada | Government Contribution 2            
Government Assistance [Line Items]            
Accounts Receivable   12,486        
Deferred Government Contribution   81,151        
Government assistance, number of times repayable grant 1.4          
Government assistance, award amount, undrawn grant funding   80,200       $ 111.8
Funding commitment received   67,800       94.4
Accrued grants receivable   12,500        
British Columbia | Government Contribution 2            
Government Assistance [Line Items]            
Accounts Receivable   17,716        
Deferred Government Contribution   24,789        
Government assistance, award amount, undrawn grant funding   43,200       60.2
Funding commitment received   25,500       $ 35.5
Accrued grants receivable   17,700        
Non-repayable            
Government Assistance [Line Items]            
Deferred Government Contribution   13,019 13,690      
Deferred Government Contribution, Current   2,299        
Deferred Government Contributions, Long-Term   10,720        
Non-repayable | Other Government Grants            
Government Assistance [Line Items]            
Deferred Government Contribution   974        
Non-repayable | Canada | Government Contribution 1            
Government Assistance [Line Items]            
Deferred Government Contribution   1,367        
Non-repayable | Canada | Government Contribution 2            
Government Assistance [Line Items]            
Deferred Government Contribution   10,678        
Non-repayable | British Columbia | Government Contribution 2            
Government Assistance [Line Items]            
Deferred Government Contribution   0        
Conditionally Repayable            
Government Assistance [Line Items]            
Deferred Government Contribution   101,561 103,247      
Deferred Government Contribution, Current   6,649        
Deferred Government Contributions, Long-Term   94,912        
Conditionally Repayable | Other Government Grants            
Government Assistance [Line Items]            
Deferred Government Contribution   0        
Conditionally Repayable | Canada | Government Contribution 1            
Government Assistance [Line Items]            
Deferred Government Contribution   76,772        
Conditionally Repayable | Canada | Government Contribution 2            
Government Assistance [Line Items]            
Deferred Government Contribution   $ 0        
Repayment period   15 years        
Conditionally Repayable | British Columbia | Government Contribution 2            
Government Assistance [Line Items]            
Deferred Government Contribution   $ 24,789        
Repayment period   15 years        
Repayable            
Government Assistance [Line Items]            
Deferred Government Contribution   $ 70,473 $ 66,499      
Deferred Government Contribution, Current   0        
Deferred Government Contributions, Long-Term   70,473        
Repayable | Other Government Grants            
Government Assistance [Line Items]            
Deferred Government Contribution   0        
Repayable | Canada | Government Contribution 1            
Government Assistance [Line Items]            
Deferred Government Contribution   0        
Expenditures incurred       $ 88,500 $ 116.9  
Repayable | Canada | Government Contribution 2            
Government Assistance [Line Items]            
Deferred Government Contribution   $ 70,473        
Repayment period   15 years        
Repayable | British Columbia | Government Contribution 2            
Government Assistance [Line Items]            
Deferred Government Contribution   $ 0